Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Global Payments Inc (GPN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Global Payments Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Global Payments Inc trades at $73.2 (market cap $21.22B). The key difference: Global Payments Inc is far larger — about 4.7× ACADIA Pharmaceuticals Inc.'s market cap, and Global Payments Inc pays a 1.29% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | GPN | |
|---|---|---|
Market Cap | $4.49B | $21.22B |
Sector | Health | Industrials |
52-Week High | $28.06 | $90.01 |
52-Week Low | $20.06 | $62.47 |
Enterprise Value | $3.69B | $38.94B |
Dividend Yield | — | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
GPN trades at $77.59, down 1.32% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.96 exceeding expectations. Revenue for 2025 was $7.71 billion, though net income margin turned negative at -7.97% for 2026 projections. Analysts maintain a buy consensus with a $80 price target, citing growth from the Worldpay integration and new AI-powered POS launches.
The stock presents a mixed outlook: positive analyst sentiment and strategic expansions support upside, but margin pressures and rising debt pose risks. Investors should weigh the company's innovation against competitive fintech threats and macroeconomic headwinds affecting transaction volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →
